---
title: "BioPharma AI Weekly - Issue #18 (2025.05.02)"
date: 2025-05-02
categories: [Weekly News]
published: false
---

# AI Technology Updates

## FLOWR - 3D Ligand Generation & Optimization Model
- [FLOWR arXiv](https://arxiv.org/html/2504.10564v1)
- Developed by Pfizer and AstraZeneca; uses protein pocket geometry for ligand generation; 24x faster than diffusion methods.

## MIT - Boltz-1x 3D Structure Prediction Model
- [Boltz-1x Github](https://github.com/jwohlwend/boltz)
- MIT released a new biomolecule 3D structure prediction model matching AlphaFold3-level accuracy.

## Harvard - ATOMICA Cross-Modality Foundation Model
- [ATOMICA Preprint](https://www.biorxiv.org/content/10.1101/2025.04.02.646906v1?utm_source=substack&utm_medium=email)
- Trained on 2M biomolecular complexes, excels at predicting diverse molecular interactions.

## Neurosnap - NeuroBind Protein Binder Design
- [NeuroBind Service](https://neurosnap.ai/service/NeuroBind)
- Combines ML, physics, and evolution to optimize affinity, solubility, stability, and immunogenicity of binders.

# AI in BioPharma

## Tempus AI - Loop Target Discovery Platform
- [Tempus Loop](https://www.tempus.com/news/tempus-introduces-loop-an-ai-powered-target-discovery-and-validation-platform/)
- Integrates real-world and experimental data for oncology target identification using AI-driven validation.

## AstraZeneca-Tempus-Pathos AI - $200M Multimodal Foundation Model Project
- [Businesswire Article](https://www.businesswire.com/news/home/20250423683527/en/Tempus-Signs-Expanded-Strategic-Agreements-with-AstraZeneca-and-Pathos-to-Develop-the-Largest-Multimodal-Foundation-Model-in-Oncology)
- Joint project to build the largest oncology multimodal foundation model using Tempus' de-identified tumor data.

## Bayer-ConcertAI - Strategic Agreement for Oncology Data & AI
- [ConcertAI Press Release](https://www.businesswire.com/news/home/20250422295853/en/ConcertAI-Announces-Strategic-Agreement-with-Bayer-to-Accelerate-Clinical-Development-in-Precision-Oncology)
- Bayer to use ConcertAI's Translational360 platform to accelerate precision oncology trials using multimodal AI.

# Conferences & Events

No major conferences or events highlighted this week.
